Clinical Trials | April 30, 2026
Pfizer drug delivers breakthrough in late-stage blood cancer trial
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The Danish biotech company confirmed the global study will begin in the second half of 2026
Health innovations are viewed more positively than food and agricultural technologies
Landmark agreement opens market access, mobility pathways, and institutional collaboration for Ayurveda, Yoga, and holistic healthcare services
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
Rs. 40 cr buyback, 200% dividend announced
Subscribe To Our Newsletter & Stay Updated
